一種新的檢測方法測定人血清或者血漿中的1116-NS-19-9抗原，檢測結(jié)果可以用于監(jiān)測胰腺癌患者的病情。

該檢測方法用于Vitros的ECi和ECiQ免疫診斷系統(tǒng)，CA19-9檢測方法是由Ortho-Clinical診斷公司(Raritan, NJ, USA)研制開發(fā)的。根據(jù)已經(jīng)發(fā)表的文獻(xiàn)，CA 19-9水平持續(xù)增高與治療無效、疾病惡化密切相關(guān)，而水平下降表示治療有效。

這套免疫診斷系統(tǒng)使用了具有知識產(chǎn)權(quán)的增強(qiáng)化學(xué)發(fā)光檢測技術(shù)，能夠增加檢測性能，檢測范圍、精確性和敏感性都大大提高。ECi和ECiQ系統(tǒng)還使用Intellicheck技術(shù)來驗(yàn)證自動樣本處理和檢測過程，增加了結(jié)果的完整性和安全性。

Assay for Monitoring Pancreatic Cancer
 
A new assay measures the 1116-NS-19-9 defined antigen in human serum or plasma, and the results can be used to monitor the status of patients with pancreatic cancer.

Designed for use on the Vitros ECi and ECiQ immunodiagnostic systems, the CA19-9 assay was developed by Ortho-Clinical Diagnostics (Raritan, NJ, USA). According to published literature, steadily increasing CA 19-9 assay levels may be correlated with ineffective therapy and progressive malignancy, while decreasing levels may indicate a response to effective therapy.

The immunodiagnostic system uses proprietary enhanced chemiluminescence detection technology, which provides good assay performance, including wide dynamic ranges, precision, and sensitivity. The ECi and ECiQ systems also use Intellicheck technology to verify diagnostic checks throughout automated sample and assay processing, which increases the integrity and security of patient results.